Coopervision Inc 5870 Stoneridge Drivesuite 1pleasanton Ca 94588 Pma Numberp180035 Supplement Numbers015 Date Received12 19 2022 Decision Date01 13 2023 Product Code Qit Advisory Committee Ophthalmic Supplement Typenormal 180 Day Track No User Fee Supplement Reason Postapproval Study Protocol Expedited Review Granted No

FDA Filings

This page includes the latest FDA filings for Coopervision Inc 5870 Stoneridge Drivesuite 1pleasanton Ca 94588 Pma Numberp180035 Supplement Numbers015 Date Received12 19 2022 Decision Date01 13 2023 Product Code Qit Advisory Committee Ophthalmic Supplement Typenormal 180 Day Track No User Fee Supplement Reason Postapproval Study Protocol Expedited Review Granted No. Currently, you will find the latest 100 filings for Premarket Notifications, Premarket Applications, De Novo Applications, and GUDID registrations.

FDA Filings

Device Company	Device	Date
PMA P180035S015 CooperVision, Inc.5870 Stoneridge Drivesuite 1pleasanton, CA 94588 PMA NumberP180035 Supplement NumberS015 Date Received12/19/2022 Decision Date01/13/2023 Product Code QIT  Advisory Committee Ophthalmic Supplement Typenormal 180 Day Track No User Fee Supplement Reason Postapproval Study Protocol Expedited Review Granted? No	MiSight 1 Day (omafilcon A) Soft (Hydrophilic) Contact Lenses for Daily Wear	2023-01-13